Association between benzodiazepine receptor agonist use and mortality in patients hospitalised for COVID-19: a multicentre observational study.
Nicolas HoertelMarina Sánchez-RicoE GulbinsJ KornhuberR VernetN BeekerA NeurazC BlancoM OlfsonG AiragnesC LemogneJesús M AlvaradoM ArnaoutC CougouleP MenetonF Limosinnull nullPublished in: Epidemiology and psychiatric sciences (2022)
BZRA use may be associated with an increased mortality among patients hospitalised for COVID-19, suggesting the potential benefit of decreasing dose or tapering off gradually these medications when possible.
Keyphrases
- coronavirus disease
- sars cov
- end stage renal disease
- cardiovascular events
- newly diagnosed
- ejection fraction
- chronic kidney disease
- risk factors
- peritoneal dialysis
- prognostic factors
- type diabetes
- randomized controlled trial
- cardiovascular disease
- respiratory syndrome coronavirus
- risk assessment
- community acquired pneumonia
- double blind
- patient reported outcomes
- patient reported